<DOC>
	<DOCNO>NCT02810132</DOCNO>
	<brief_summary>The study evaluate effect metformin treatment myocardial efficiency heart failure patient . 36 patient randomize three month metformin placebo treatment addition regular therapy . Hypothesis : Treatment metformin patient heart failure direct indirect beneficial effect leave ventricular myocardial oxidative metabolism , myocardial efficiency contractile function .</brief_summary>
	<brief_title>Effects Metformin Treatment Myocardial Efficiency Patients With Heart Failure</brief_title>
	<detailed_description>Background : Heart failure ( HF ) common disease diabetes/insulin resistance present approximately 50 % HF patient . Metformin commonly prescribe oral anti-diabetic drug , registry experimental study show beneficial effect metformin HF , randomize trial need . Objectives : To investigate treatment metformin patient HF beneficial effect myocardial efficiency , Design : A randomized , double-blind , placebo-controlled , single-center design . 36 patient systolic heart failure randomize either metformin ( N = 18 ) placebo ( N= 18 ) 3 month . Methods : Patients undergo echocardiography rest exercise along [ 11C ] -acetate PET . Primary outcome parameter change myocardial external efficiency visit 1 3 month therapy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients chronic heart failure uptitrated recommend maximally tolerate dose ACEI/ARB ( unless contraindicate ) betablocker ( unless contraindicate ) . If indicate , aldosterone receptor antagonist give ( unless contraindicate ) . An ICD and/or CRT implant , indicate . Patients CRT device treat &gt; 3 month . LVEF &lt; 45 % NYHAclass II , III IV Relatively preserve renal function ( eGFR &gt; 30 ml/min ) Ability understand write patient information give inform consent Negative urineHCG woman childbearing potential Patients must insulin resistance , define 1 follow criterion : 1 . HbA1c 5.5 6.4 % ( 37 47 mmol/mol ) within last 12 month prior enrolment 2 . Impaired fast glucose ( IFG ) : Fasting Pglucose 5.6 6.9 mmol/l within 12 month prior enrolment ( patient stable condition ) 3 . Impaired glucose tolerance ( IGT ) OGTT perform time prior enrolment : Fasting Pglucose &lt; 7.0 mmol/l 2 hour Pglucose 7.8 11.0 mmol/l Metformin treatment within last 3 month Known allergy metformin major side effect metformin treatment Acute myocardial infarction , unstable angina revascularization &lt; 3 month time randomization Planned coronary revascularization Significant , uncorrected cardiac valve disease Cardiac arrest life threaten ventricular arrhythmia within last 3 month ( unless treat ICD ) Atrial fibrillation poorly control ventricular rate rest ( &gt; 100 beats/min ) Hypertrophic restrictive cardiomyopathy , infiltrative storage myocardial disease , active myocarditis , pericardial disease . Planned major surgery Female patient pregnant , nursing , childbearing potential practicing effective chemical contraceptive method ( i.e . oral , implanted , injectable , transdermal contraceptive hormone ; intrauterine device ) Age &lt; 18 year Current abuse alcohol drug Cancer , lifeexpectancy le 2 year Stroke within last 6 month Liver disease PALAT &gt; 3 time upper normal limit ( possible repeat measurement within month ) Significant comorbidity issue make patient unsuitable participation judge investigator Participation another study involve longterm medical intervention ( participation device study allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>